A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML

Leukemia. 2017 Jun;31(6):1466-1470. doi: 10.1038/leu.2017.84. Epub 2017 Mar 10.

L M Kats^{1

2}, S J Vervoort¹, R Cole¹, A J Rogers¹, G P Gregory^{1

2

3}, E Vidacs¹, J Li^{2

4}, R Nagaraja⁵, K E Yen⁵, R W Johnstone^{1

2}

¹ Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
³ Monash Haematology, Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
⁴ Bioinformatics Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁵ Agios Pharmaceuticals, Cambridge, MA, USA.

No abstract available

Publication types